Avanzanite Bioscience has secured a €32 million Series A investment from MVM Partners, marking the company’s first institutional financing and positioning it for an accelerated phase of commercial and strategic growth across Europe’s rare disease landscape.
The Amsterdam-based specialty pharmaceutical company, founded in 2022, has rapidly emerged as a key partner for biotech and pharmaceutical innovators seeking to commercialize orphan medicines across all 32 European markets. The new funding will significantly expand Avanzanite’s pan-European infrastructure, support ongoing and upcoming product launches, and fuel additional alliances and acquisitions designed to broaden its portfolio.
The investment follows a record quarter for the company. Avanzanite’s revenue tripled year on year in Q3 2025 and rose more than 20 percent compared with the previous quarter. Over its first three years, the company has entered three strategic alliances and launched three rare disease medicines across nephrology, ophthalmology, and haematology, with exclusive rights across the European Economic Area, the UK, and Switzerland.
Avanzanite was created to solve the long-standing access challenge for rare disease medicines in Europe. Its fully integrated model centralizes commercial strategy, scientific expertise, market access, pricing, and reimbursement under a single pan-European operation. This approach aims to create a new standard for patient access while enabling innovators to deploy orphan medicines efficiently and at scale across the continent.
The Series A financing comes from MVM’s €500 million sixth fund, with the firm committing up to €32 million and reserving additional capital to support Avanzanite’s long-term growth. MVM will also join Avanzanite’s Board of Directors.
With this fresh capital, Avanzanite plans to advance toward its 2032 vision of a pan-European platform comprising more than ten rare disease alliances, expanding its commercial footprint and deepening its role as a preferred launch partner for companies bringing breakthrough therapies to European patients.
KEY QUOTES
“For years MVM has watched promising rare disease medicines struggle to find a path to patients – Avanzanite breaks this pattern. In a short space of time, Avanzanite has successfully launched multiple rare disease products. Their experienced leadership team and pan-European footprint make them the stand-out partner. We are excited to support Avanzanite in bringing more transformative therapies to patients across Europe.”
Dr. Jack Tanaka, Partner at MVM
“We are truly honored to partner with MVM, a top-tier investor in life sciences. Their investment is far more than capital – it demonstrates conviction in our mission and belief in the ‘Champions League’ team that powers Avanzanite. With MVM’s support we will scale faster, expand with new partnerships and assets, and advance towards our 2032 vision of a pan-European platform with more than ten rare disease alliances – setting a new European standard for orphan medicine commercialisation and patient access. While this milestone reflects how far we’ve come, it is just the beginning of our journey.”
Adam Plich, Founder and CEO of Avanzanite
